Biotech Values

[DewDiligence]

I just listened to the relevant portion of IDIX’s CC. The discussion of interest was prompted by a question from Rachel McMinn asking how IDIX could go into phase-3 with so few patients in the IDX184 safety database. Doug Mayers, CMO, replied that more safety data will indeed be needed to go into phase-3 (the current phase-2b has only 100 patients), but IDIX expects to have enough cumulative patients from the various phase-2 trials it plans to run.

In other words, there is no requirement per se for IDIX to run several more phase-2 trials just to make a go/no-go decision on phase-3; however, there is a requirement for a larger safety database, and IDIX intends to meet this requirement by running multiple, small phase-2 trials rather than one large one.

All told, my impression is that IDIX is flailing (as noted in my prior post in this thread). They don’t really know what they intend to accomplish with the IDX184 phase-2 program, but they hope that something they are doing will spark an interest from somebody.